CN117771240A - Application of levetiracetam in preparation of weight-losing medicines - Google Patents
Application of levetiracetam in preparation of weight-losing medicines Download PDFInfo
- Publication number
- CN117771240A CN117771240A CN202311652436.4A CN202311652436A CN117771240A CN 117771240 A CN117771240 A CN 117771240A CN 202311652436 A CN202311652436 A CN 202311652436A CN 117771240 A CN117771240 A CN 117771240A
- Authority
- CN
- China
- Prior art keywords
- acid
- levetiracetam
- weight
- losing
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004002 levetiracetam Drugs 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 26
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title claims abstract 11
- 229940079593 drug Drugs 0.000 title abstract description 16
- 238000002360 preparation method Methods 0.000 title description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims abstract description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims abstract description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims abstract description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims abstract description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims abstract description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960000583 acetic acid Drugs 0.000 claims abstract description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims abstract description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 3
- 229960004106 citric acid Drugs 0.000 claims abstract description 3
- 239000001530 fumaric acid Substances 0.000 claims abstract description 3
- 229960002598 fumaric acid Drugs 0.000 claims abstract description 3
- 239000004310 lactic acid Substances 0.000 claims abstract description 3
- 229960000448 lactic acid Drugs 0.000 claims abstract description 3
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 3
- 239000011976 maleic acid Substances 0.000 claims abstract description 3
- 229940098895 maleic acid Drugs 0.000 claims abstract description 3
- 229960002510 mandelic acid Drugs 0.000 claims abstract description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims abstract description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960003424 phenylacetic acid Drugs 0.000 claims abstract description 3
- 239000003279 phenylacetic acid Substances 0.000 claims abstract description 3
- 229960004838 phosphoric acid Drugs 0.000 claims abstract description 3
- 229940107700 pyruvic acid Drugs 0.000 claims abstract description 3
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 3
- 229940032330 sulfuric acid Drugs 0.000 claims abstract description 3
- 239000011975 tartaric acid Substances 0.000 claims abstract description 3
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 3
- 229960001367 tartaric acid Drugs 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000244206 Nematoda Species 0.000 abstract description 12
- 208000008589 Obesity Diseases 0.000 abstract description 10
- 235000020824 obesity Nutrition 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000037396 body weight Effects 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 abstract description 5
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 238000013116 obese mouse model Methods 0.000 abstract description 3
- 150000007513 acids Chemical class 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract description 2
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 24
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 7
- 239000005642 Oleic acid Substances 0.000 description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of levetiracetam or a medicinal salt thereof in preparing a weight-losing medicament. The pharmaceutically acceptable salt is an acid addition salt of levetiracetam with the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, tartaric acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid. The animal experiment of the invention can obviously inhibit OA-induced nematode obesity by using levetiracetam on caenorhabditis elegans; the use of levetiracetam on C56BL/6J mice significantly reduced the body weight of DIO obese mice. The result of the drug effect experiment shows that levetiracetam has remarkable weight-losing effect and can be used as a weight-losing drug.
Description
Technical Field
The invention belongs to the technical field of drug development, and particularly relates to an application of levetiracetam in preparation of weight-losing drugs.
Background
Obesity is an increasing health problem worldwide, being closely related to a number of serious health risks, including cardiovascular disease, diabetes, hypertension, certain cancers, and bone joint problems. Treatment and management of obesity has long been an important area of clinical and scientific research. Traditional methods of obesity treatment include diet control, physical exercise, medication, surgery, and the like. However, some drug therapies and surgical approaches are accompanied by non-negligible side effects and limitations of synthetic drugs. Thus, there is a need to find safer, more effective treatments for obesity. Drug repositioning discovery is an emerging field of research aimed at reusing existing drugs or finding new uses to meet the therapeutic needs of different diseases. This approach has great potential in the area of weight loss medicine because it can provide a new approach to treating obesity, reduce the time and cost of drug development, and reduce the risk of side effects. In the prior art, several obesity treatment drugs have been developed. These drugs generally reduce body weight by suppressing appetite, promoting metabolism, improving energy balance, or affecting mechanisms such as food digestion and absorption. However, these drugs are often associated with side effects, drug interactions and sustainability issues for long term use.
Levetiracetam (CAS number 102767-28-2) is an antiepileptic drug for the treatment of epilepsy and epilepsy-related disorders. The structure of levetiracetam is as follows:
it was first approved by the FDA in 1999 and has become one of the first line of therapeutic agents commonly used clinically. Levetiracetam has been widely used clinically at present for the treatment of various types of seizures, including partial seizures, systemic seizures, and special kinds of epileptic symptoms, often with other antiepileptic drugs to provide a more comprehensive therapeutic effect. No report on the weight loss of the obese people by using levetiracetam is known up to the present.
Disclosure of Invention
The invention aims to provide an application of levetiracetam in preparing a weight-losing medicament.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the invention provides an application of levetiracetam or a medicinal salt thereof in preparing a weight-losing medicament.
The pharmaceutically acceptable salt is an acid addition salt of levetiracetam with the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, tartaric acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid, and the like.
The structure of levetiracetam is as follows:
the invention provides an application of levetiracetam or medicinal salt thereof in preparing a weight-losing medicament, wherein the levetiracetam or the medicinal salt thereof is taken as a single active ingredient in the application.
The invention also provides a pharmaceutical preparation prepared from levetiracetam or the pharmaceutical salt thereof, and pharmaceutically acceptable auxiliary materials or other pharmaceutically acceptable components.
The dosage forms of the pharmaceutical preparation are injection, capsule, tablet, granule, pill, microcapsule preparation, microsphere preparation, nanometer preparation and the like.
By adopting the technical scheme, the invention has the following advantages and beneficial effects:
the animal experiment of the invention can obviously inhibit OA-induced nematode obesity by using levetiracetam on caenorhabditis elegans; the use of levetiracetam on C56BL/6J mice significantly reduced the body weight of DIO obese mice.
The result of the drug effect experiment shows that levetiracetam has remarkable weight-losing effect and can be used as a weight-losing drug.
Drawings
FIG. 1 is a schematic representation of nematode fat content of example 1.
Figure 2 is a graphical representation of animal body weight as a function of time for example 2.
FIG. 3 is a graph showing the rate of change of body weight of animals in example 2.
Detailed Description
In order to more clearly illustrate the present invention, the present invention will be further described with reference to preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and that this invention is not limited to the details given herein.
Example 1
1.1 construction of nematode obesity model
The addition of Oleic Acid (OA) to food can significantly increase the fat accumulation of nematodes. Also, by using OilRed-O (ORO) staining, it was found that the ORO level was significantly elevated when animals were fed with OA as compared to OP50 medium, based on which a fat accumulation model (PMID: 35140229) was established.
1.2 laboratory apparatus
An electron microscope.
1.3 Experimental procedure
Caenorhabditis elegans is fed with HFD to L4 larvae, synchronized L1 larvae are grown on NGM plates fed with HFD to L4 larvae, and then transferred to NGM plates with normal diet. And (5) respectively adding different medicines into the OP50 bacterial liquid, and coating the medicines and the bacterial liquid on a plate. Blank group: OP50 bacterial liquid; OA group: mixing 4mM OA with OP50 bacterial liquid; levetiracetam group: 4mM OA was mixed with OP50 bacteria solution and levetiracetam was given at a dose of 0.3. Mu.M.
1.4 observations index
Oil red O staining method: nematodes were fixed in 4% paraformaldehyde solution and gently shaken at room temperature for 1 hour. The immobilized nematodes were washed with 1 XPBS, resuspended in 60% isopropanol and incubated for 15 min at room temperature. Then incubated with saturated ORO staining solution in 60% isopropanol with shaking and nematode staining overnight. Thereafter, the nematodes were washed twice with 1 XPBS 0.01% Triton X-100 to remove excess dye. The nematodes were then fixed on 2% agar plates and imaged with a microscope at x 10 magnification. All conditions in each experiment used the same exposure settings.
1.5 experimental results
Levetiracetam has a remarkable inhibitory effect on OA-induced nematode obesity at a concentration of 0.3 μm, and the results are shown in fig. 1, and fig. 1 is a schematic diagram of nematode fat content.
Example 2
2.1 construction of DiO obese model mice
26 mice (C56 BL/6J, kwangsi laboratory animals Co., ltd.) of 18-22 g at 8 weeks of age were prepared, randomly distributed using a random number table according to a random distribution principle, and 6 cages were used per cage, and the diet was fed for 12 weeks.
2.2 laboratory apparatus
An electronic balance.
2.3 Experimental procedure
After 12 weeks of feeding, the animals were randomly assigned again according to the random number method and divided into 3 groups, and different drugs were administered according to the experimental schedule for 4 consecutive weeks, during which time free high-fat diet and water intake were continued. Blank (n=9): administration by gastric lavage is carried out once a day, and physiological saline with the same volume as the administration group is administered; levetiracetam group (n=9): the medicine is administrated by stomach irrigation once a day, and the dosage is 125mg/kg; positive drug liraglutide group (n=8): subcutaneous injections are given twice daily at a dose of 0.1mg/kg.
2.4 observations index
The weight change of each group of mice was recorded and weighed once every 7 days.
2.5 experimental results
Experimental data were plotted and analyzed using software GraphPad Prism 9. The comparison between groups was significantly different from P <0.05 using One-Way ANOVA analysis.
The significant weight loss of mice treated with levetiracetam at a dose of 125mg/kg was significantly different from that of the blank group, which indicates that levetiracetam has a significant effect on weight loss of obese mice at a dose of 125mg/kg, and the results are shown in fig. 2 and 3, and fig. 2 is a graph showing the change of animal weight with time. FIG. 3 is a graph showing the rate of change of animal body weight.
The result of the drug effect experiment shows that levetiracetam has remarkable weight-losing effect and can be used as a weight-losing drug.
The foregoing description is only illustrative of the preferred embodiment of the present invention, and is not to be construed as limiting the invention, but is to be construed as limiting the invention to any and all simple modifications, equivalent variations and adaptations of the embodiments described above, which are within the scope of the invention, may be made by those skilled in the art without departing from the scope of the invention.
Claims (3)
1. Application of levetiracetam or pharmaceutically acceptable salt thereof in preparing weight-reducing medicine is provided.
2. Use of levetiracetam or a pharmaceutically acceptable salt thereof as claimed in claim 1 for the manufacture of a medicament for reducing weight, wherein the pharmaceutically acceptable salt is an acid addition salt of levetiracetam with: hydrochloric acid, hydrobromic acid, sulfuric acid, lactic acid, citric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, tartaric acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid.
3. Use of levetiracetam or a pharmaceutically acceptable salt thereof as claimed in claim 1 for the manufacture of a medicament for reducing weight, characterized in that the structure of levetiracetam is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311652436.4A CN117771240A (en) | 2023-12-05 | 2023-12-05 | Application of levetiracetam in preparation of weight-losing medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311652436.4A CN117771240A (en) | 2023-12-05 | 2023-12-05 | Application of levetiracetam in preparation of weight-losing medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117771240A true CN117771240A (en) | 2024-03-29 |
Family
ID=90396967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311652436.4A Pending CN117771240A (en) | 2023-12-05 | 2023-12-05 | Application of levetiracetam in preparation of weight-losing medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117771240A (en) |
-
2023
- 2023-12-05 CN CN202311652436.4A patent/CN117771240A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527599A (en) | Use of zonisamide in obesity and eating disorders | |
| US9555055B2 (en) | Use of albiflorin and metabolites thereof | |
| CN103385884A (en) | Application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease | |
| Yan et al. | Effects of vestibular damage on the sleep and expression level of orexin in the hypothalamus of rats and its correlation with autophagy and Akt tumor signal pathway | |
| CN109432071A (en) | Xanthohumol is inhibiting the application in the aggregation of Tau abnormal protein | |
| CN117771240A (en) | Application of levetiracetam in preparation of weight-losing medicines | |
| CN103860575A (en) | Application of geniposide used as acetylcholin esterase inhibitor | |
| CN112494505A (en) | Application of echinacoside in preparation of medicine for treating neuropathic pain | |
| CN1723936A (en) | Traditional Chinese medicine for treating depressive disorders, and its prepn. method | |
| CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
| CN108451951A (en) | A kind of new drug for treating neurogenic disease | |
| AU2022200277A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
| CN107375311A (en) | Liquiritin treats the pharmaceutical applications of neurogenic pain | |
| CN106943408B (en) | Application of tetramethyluric acid in preventing and treating diabetes | |
| CN1401317A (en) | Use of bismuth subgallate in suppressing formation of nitrogen oxide synthetase | |
| CN110003157A (en) | A kind of novel flavone compound and its application with angst resistance effect | |
| CN109260184A (en) | Corylifolinin is inhibiting the application in the aggregation of Tau abnormal protein | |
| CN1636581A (en) | Safflower medicine composition and its prepn process and use | |
| CN108864015A (en) | It is a kind of to have effects that treat the compound and pharmaceutical composition of neurodegenerative disease | |
| CN104224808A (en) | Protective function of minocycline for offspring neuropsychiatric injury caused by stress during pregnancy | |
| CN107137391A (en) | Purposes of the dihydromyricetin in terms of the medicine for the treatment of depression is prepared | |
| CN106821975A (en) | A kind of Mo Naitaier oral liquids and its preparation method and application | |
| RU2077888C1 (en) | Method of treatment of radiation disease in animals | |
| CN115778944A (en) | Application of osthole in preparing medicine for improving or treating cognitive dysfunction | |
| RU2447893C1 (en) | Drug preparation 'kholvakor' in form of alcoholic solution for control of lipid metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |